Amphetamine-Induced Displacement of [18F] Fallypride in Striatum and Extrastriatal Regions in Humans
The DOI matches its Crossref record; 107 of the 107 references it cites were found in a registry or an index.
Abstract
This study examined D-amphetamine (D-AMPH)-induced displacements of [18F] fallypride in striatal and extrastriatal regions and the correlations of these displacements with cognition, affect, and sensation-seeking behavior. In all, 14 normal subjects, six females and eight males (ages 21-32, mean age 25.9 years), underwent positron emission tomography (PET) with [18F]fallypride before and 3 h after a 0.43 mg/kg oral dose of D-AMPH. Levels of dopamine (DA) D2 receptor density were calculated with the reference region method of Lammerstma. Percent displacements in striatal and extrastriatal regions were calculated for the caudate, putamen, ventral striatum, medial thalamus, amygdala, substantia nigra, and temporal cortex. Correlations of changes in cognition, affect, and sensation seeking with parametric images of D-AMPH-induced DA release were computed. Significant displacements were seen in the caudate, putamen, ventral striatum substantia nigra, and temporal cortex with a trend level change in the amygdala. Greatest displacements were seen in striatal subdivisions-5.6% in caudate, 11.2% in putamen, 7.2% in ventral striatum, and 6.6% in substantia nigra. Lesser decrements were seen in amygdala-4.4%, temporal cortex-3.7%, and thalamus-2.8%. Significant clusters of correlations of regional DA release with cognition and sensation-seeking behavior were observed. The current study demonstrates that [18F]fallypride PET studies using oral D-AMPH (0.43 mg/kg) can be used to study D-AMPH-induced DA release in the striatal and extrastriatal regions in humans, and their relationship with cognition and sensation-seeking behavior.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Development and validation of brief measures of positive and negative affect: The PANAS scales.
Watson, D., Clark, L. A., & Tellegen, A. (1988) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.54.6.1063 · Cited by 32,433
Wechsler Adult Intelligence Scale-III
Ryan, J. J., & Lopez, S. J. (2001) · Understanding Psychological Assessment · doi:10.1007/978-1-4615-1185-4_2 · Cited by 3,731
Forman, S. D., Cohen, J. D., Fitzgerald, M., Eddy, W. F., Mintun, M. A., & Noll, D. C. (1995) · Magnetic Resonance in Medicine · doi:10.1002/mrm.1910330508 · Cited by 3,202
Drug Addiction, Dysregulation of Reward, and Allostasis
Koob, G. (2001) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00195-0 · Cited by 2,953
Sensation seeking in England and America: cross-cultural, age, and sex comparisons
Zuckerman, M., Eysenck, S. B., & Eysenck, H. J. (1978) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.46.1.139 · Cited by 1,905
The Structured Clinical Interview for DSM-III-R (SCID): II. Multisite Test-Retest Reliability
Williams, J. B. W. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080038006 · Cited by 1,618
D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory
Sawaguchi, T., & Goldman-Rakic, P. S. (1991) · Science · doi:10.1126/science.1825731 · Cited by 1,364 · cited 2×
“Frontal cortical dopaminergic neurotransmission has been shown to modulate spatial working memory (Sawaguchi and Goldman-Rakic, 1991).”
BackgroundLaruelle, M., Abi-Dargham, A., van Dyck, C. H., Gil, R., D'Souza, C. D., Erdos, J., McCance, E., Rosenblatt, W., Fingado, C., Zoghbi, S. S., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9235 · Cited by 1,291 · cited 2×
“[123I]IBZM SPECT studies of D-AMPH-induced displacements report decrements in the striatum of 7–9% in normal subjects following an intravenous dose of 0.3mg/kg (Abi-Dargham et al, 2003, 2004; Laruelle et al, 1996; Kegeles et al, 1999).”
BackgroundInfluentialSelf-citationBreier, A., Su, T.-P., Saunders, R., Carson, R. E., Kolachana, B. S., de Bartolomeis, A., Weinberger, D. R., Weisenfeld, N., Malhotra, A. K., Eckelman, W. C., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2569 · Cited by 1,154 · cited 3×
“The decrement in striatal binding potential (b.p.) or V300 for benzamide DA D2/D3 radioligands following D-AMPH administration in primates has been shown to be linearly related to the level of D-AMPH-induced DA release (Laruelle et al, 1997; Breier et al, 1997).”
BackgroundInfluentialDopamine in drug abuse and addiction: results from imaging studies and treatment implications
Volkow, N. D., Fowler, J. S., Wang, G.-J., & Swanson, J. M. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001507 · Cited by 1,101 · cited 6×
“014), substantia nigra (p¼ 0.014), and temporal cortex (po0.”
BackgroundResultInfluential
Research works printed but not linked: 1
- Mukherjee J, Christian B, Shi B, Narayanan TK, Mantil J (2002). 18F-fallypride displacement in the non- human primate brain by nicotine- induced and amphetamine-induced dopamine release. Neuroimage 16: S42.
Cited by
A review of the clinical pharmacology of methamphetamine
Cruickshank, C. C., & Dyer, K. R. (2009) · Addiction · doi:10.1111/j.1360-0443.2009.02564.x · Cited by 769
del Campo, N., Chamberlain, S. R., Sahakian, B. J., & Robbins, T. W. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.02.036 · Cited by 685
Faraone, S. V. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.02.001 · Cited by 631
“…binding in the striatum of healthy adults, as measured by PET, were correlated with increased cortisol release and positive subjective ratings of AMP Oswald et al. (2015) • AMP decreased [11C]raclopride (a D2 receptor antagonist) binding in the striatum of healthy adults, with lower…”
InfluentialIncreased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
Dopaminergic mechanisms of individual differences in human effort-based decision-making
Treadway, M. T., Buckholtz, J. W., Cowan, R. L., Woodward, N. D., Li, R., Ansari, M. S., Baldwin, R. M., Schwartzman, A. N., Kessler, R. M., & Zald, D. H. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.6459-11.2012 · Cited by 385
Kokkinou, M., Ashok, A. H., & Howes, O. D. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.190 · Cited by 247
Zald, D. H., Cowan, R. L., Riccardi, P., Baldwin, R. M., Ansari, M. S., Li, R., Shelby, E. S., Smith, C. E., McHugo, M., & Kessler, R. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.2423-08.2008 · Cited by 234
“Previous studies have demonstrated good intersubject and intratest-retest reliability for measurement of [ 18F]fallypride BPND for the DA midbrain at this scanner resolution (Mukherjee et al., 2002; Riccardi et al., 2006).”
BackgroundMethodInfluentialSelf-citationConditioned cues and the expression of stimulant sensitization in animals and humans
Vezina, P., & Leyton, M. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.070 · Cited by 213
“…al., 1995; Breier et al., 1997; Drevets et al., 2001; Leyton et al., 2002; Martinez et al., 2003, 2007; Abi-Dargham et al., 2003; Oswald et al., 2005; Riccardi et al., 2006a; Boileau et al., 2006, 2007; Munro et al., 2006; Casey et al., 2007) and cocaine (Schlaepfer et al., 1997; Cox et al., 2006).”
The dopaminergic basis of human behaviors: A review of molecular imaging studies
Egerton, A., Mehta, M. A., Montgomery, A. J., Lappin, J. M., Howes, O. D., Reeves, S. J., Cunningham, V. J., & Grasby, P. M. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.005 · Cited by 159
“…to measure extrastriatal D2 receptor availability and possibly extrastriatal DA release, high affinity antagonist radiotracers such as [11C]FLB457 and [18F]fallypride are required (Aalto et al., 2005; Montgomery et al., 2007; Riccardi et al., 2006a; Riccardi et al., 2006b; Slifstein et al., 2004).”
BackgroundDecreased Dopamine Type 2 Receptor Availability After Bariatric Surgery: Preliminary Findings
Dunn, J. P., Cowan, R. L., Volkow, N. D., Feurer, I. D., Li, R., Williams, D. B., Kessler, R. M., & Abumrad, N. N. (2010) · Brain Research · doi:10.1016/j.brainres.2010.03.064 · Cited by 151
“, 2003) and [18F] fallypride (Mark et al., 2004; Riccardi et al., 2006) in comparable ROIs.”
BackgroundResultSelf-citationTowers, E. B., Williams, I. L., Qillawala, E. I., Rissman, E. F., & Lynch, W. J. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000361 · Cited by 173
Dunn, J. P., Kessler, R. M., Feurer, I. D., Volkow, N. D., Patterson, B. W., Ansari, M. S., Li, R., Marks-Shulman, P., & Abumrad, N. N. (2012) · Diabetes Care · doi:10.2337/dc11-2250 · Cited by 148
“As the measure of DA D2R availability used in this study, [(18)F]fallypride BPND is sensitive to extracellular DA levels; increases or decreases in extracellular DA levels will produce apparent decreases or increases in BPND, respectively (14).”
BackgroundMethodSelf-citationKessler, R. M., Woodward, N. D., Riccardi, P., Li, R., Ansari, M. S., Anderson, S., Dawant, B., Zald, D., & Meltzer, H. Y. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2008.12.029 · Cited by 136
“The amygdala can be visualized in the on MRI scans just anterior to the tip of the temporal horn of the lateral ventricle and deep to the uncus (57); the amygdala is located 6 to 20 mm below the ACPC line, 12 to 28 mm lateral to the midline, and from 2 to 12 mm behind the plane of the anterior commissure (56).”
InfluentialSelf-citationNarendran, R., Frankle, W. G., Mason, N. S., Rabiner, E. A., Gunn, R. N., Searle, G. E., Vora, S., Litschge, M., Kendro, S., Cooper, T. B., et al. (2009) · Synapse · doi:10.1002/syn.20628 · Cited by 130
Conditioned and sensitized responses to stimulant drugs in humans
Leyton, M. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.08.027 · Cited by 127
The HR/LR model: further evidence as an animal model of sensation seeking
Blanchard, M. M., Mendelsohn, D., & Stamp, J. A. (2009) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2009.05.009 · Cited by 121
Occupancy of Striatal and Extrastriatal Dopamine D2 Receptors by Clozapine and Quetiapine
KESSLER, R. M., Ansari, M. S., Riccardi, P., Li, R., Jayathilake, K., Dawant, B. M., & Meltzer, H. Y. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301108 · Cited by 135
“…2002) the high intersubject reliability for the substantia nigra we have reported in normal subjects–an 8% coefficient of variation across subjects (Riccardi et al, 2006), and the high correlation between PET [18F]fallypride binding potentials in extrastriatal regions of human brain, including…”
BackgroundSelf-citationKambeitz, J., Abi-Dargham, A., Kapur, S., & Howes, O. D. (2014) · British Journal of Psychiatry · doi:10.1192/bjp.bp.113.132308 · Cited by 115
Striatal and extrastriatal dopamine release measured with PET and [18F] fallypride
Slifstein, M., Kegeles, L. S., Xu, X., Thompson, J. L., Urban, N., Castrillon, J., Hackett, E., Bae, S. ‐., Laruelle, M., & Abi‐Dargham, A. (2010) · Synapse · doi:10.1002/syn.20734 · Cited by 115
“%) decreases in subregions containing caudate, in closer agreement with this study and (Martinez et al., 2003) than with (Cropley et al., 2008;Riccardi et al., 2006a), supporting the role of mode of administration on observed amphetamine effect.”
BackgroundMethodResultInfluentialdel Campo, N., Fryer, T. D., Hong, Y. T., Smith, R., Brichard, L., Acosta-Cabronero, J., Chamberlain, S. R., Tait, R., Izquierdo, D., Regenthal, R., et al. (2013) · Brain · doi:10.1093/brain/awt263 · Cited by 113
“…BPND % change across subregions of the striatum and the midbrain were comparable with those docu- mented following oral administration of amphetamine (Riccardi et al., 2006a; Cropley et al., 2008) (Supplementary material), the alternative first-line treatment for ADHD which also…”
MethodResultImpulsivity and chronic stress are associated with amphetamine-induced striatal dopamine release
Oswald, L. M., Wong, D. F., Zhou, Y., Kumar, A., Brasic, J., Alexander, M., Ye, W., Kuwabara, H., Hilton, J., & Wand, G. S. (2007) · NeuroImage · doi:10.1016/j.neuroimage.2007.01.055 · Cited by 108
Willeit, M., Ginovart, N., Graff, A., Rusjan, P., Vitcu, I., Houle, S., Seeman, P., Wilson, A. A., & Kapur, S. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301400 · Cited by 107
Cropley, V. L., Innis, R. B., Nathan, P. J., Brown, A. K., Sangare, J. L., Lerner, A., Ryu, Y. H., Sprague, K. E., Pike, V. W., & Fujita, M. (2008) · Synapse · doi:10.1002/syn.20506 · Cited by 104
“As expected, the magnitude of this displacement was slightly higher than that reported by Riccardi et al. (2006) using [18F]fallypride and a slightly lower dose (0.43 mg/kg) of oral amphetamine.”
BackgroundResultInfluentialWoodward, N. D., Cowan, R. L., Park, S., Ansari, M. S., Baldwin, R. M., Li, R., Doop, M., Kessler, R. M., & Zald, D. H. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10020165 · Cited by 90
“Fourteen participants in the openlabel cohort were included in a previous report (21).”
BackgroundMethodResultInfluentialSelf-citationEisenstein, S. A., Antenor‐Dorsey, J. A. V., Gredysa, D. M., Koller, J. M., Bihun, E. C., Ranck, S. A., ArbelÁez, A. M., Klein, S., Perlmutter, J. S., Moerlein, S. M., et al. (2013) · Synapse · doi:10.1002/syn.21680 · Cited by 87
“Second, endogenous dopamine release decreases specific binding of [(11)C]raclopride, [(18)F]fallypride, or [(123)I]IBZM (Dewey et al., 1993; Laruelle et al., 1995; Riccardi et al., 2006), making these radioligands useful to measure endogenous dopamine release but confounding interpretation of D2=D3 receptor availabili…”
BackgroundInfluentialKegeles, L. S., Slifstein, M., Xu, X., Urban, N., Thompson, J. L., Moadel, T., Harkavy-Friedman, J. M., Gil, R., Laruelle, M., & Abi-Dargham, A. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.05.027 · Cited by 82
Chuhma, N., Mingote, S., Kalmbach, A., Yetnikoff, L., & Rayport, S. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2016.07.002 · Cited by 82
Impact of D2 Receptor Internalization on Binding Affinity of Neuroimaging Radiotracers
Guo, N., Guo, W., Kralikova, M., Jiang, M., Schieren, I., Narendran, R., Slifstein, M., Abi-Dargham, A., Laruelle, M., Javitch, J. A., et al. (2010) · Neuropsychopharmacology · doi:10.1038/npp.2009.189 · Cited by 80
“…I]IBZM (K D = 0.2 nM), and [ 18 F]fallypride (K D = 0.2 nM) (Cropley et al , 2008; Laruelle, 2000; Mukherjee et al , 2005; Narendran et al , 2009; Riccardi et al , 2006; Slifstein et al , 2004), but inconsistently with the very-high affinity D 2 receptor antagonists [ 11 C]N-methylspiperone ([…”
InfluentialApplication of cross-species PET imaging to assess neurotransmitter release in brain
Finnema, S. J., Scheinin, M., Shahid, M., Lehto, J., Borroni, E., Bang-Andersen, B., Sallinen, J., Wong, E., Farde, L., Halldin, C., et al. (2015) · Psychopharmacology · doi:10.1007/s00213-015-3938-6 · Cited by 78
“…in cortical synaptic dopamine concentrations in monkeys and human subjects (Aalto et al. 2009; Cropley et al. 2008; Mukherjee et al. 2005; Narendran et al. 2009; Narendran et al. 2013; Narendran et al. 2014; Riccardi et al. 2006; Sandiego et al. 2015; Slifstein et al. 2010; Slifstein et al. 2004).”
BackgroundKessler, R. M., Zald, D. H., Ansari, M. S., Li, R., & Cowan, R. L. (2014) · Synapse · doi:10.1002/syn.21738 · Cited by 77
“(Riccardi et al., 2006).”
MethodResultInfluentialSelf-citationNarendran, R., Mason, N. S., Laymon, C. M., Lopresti, B. J., Velasquez, N., May, M. A., Kendro, S., Martínez, D., Mathis, C. A., & Frankle, W. G. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.163501 · Cited by 86
Tournier, B. B., Steimer, T., Millet, P., Moulin-Sallanon, M., Vallet, P., Ibañez, V., & Ginovart, N. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145713000205 · Cited by 76
“Similarly, novelty- (Leyton et al., 2002) and sensation- (Riccardi et al., 2006) seeking in humans was found to correlate with Amph-induced DA release, as assessed by reductions in [11C]raclopride or [18F]Fallypride binding.”
Woodward, N. D., Zald, D. H., Ding, Z., Riccardi, P., Ansari, M. S., Baldwin, R. M., Cowan, R. L., Li, R., & Kessler, R. M. (2009) · NeuroImage · doi:10.1016/j.neuroimage.2009.01.049 · Cited by 72
“…ROIs were selected because they represent the greatest targets of midbrain DA projections, have significant D 2 /D 3 receptor levels, and are frequently the focus of neuroreceptor mapping studies examining group differences in DA D 2 /D 3 levels (Mukherjee et al., 2002; Riccardi et al., 2006a).”
Self-citationDopaminergic Neurotransmission in the Human Brain: New Lessons from Perturbation and Imaging
Ko, J. H., & Strafella, A. P. (2012) · The Neuroscientist · doi:10.1177/1073858411401413 · Cited by 68
Measuring extrastriatal dopamine release during a reward learning task
Vrieze, E., Ceccarini, J., Pizzagalli, D. A., Bormans, G., Vandenbulcke, M., Demyttenaere, K., Van Laere, K., & Claes, S. (2013) · Human Brain Mapping · doi:10.1002/hbm.21456 · Cited by 63
“…low D2/D3 receptor density in vivo, including the extrastriatal reward circuit [Aalto et al., 2005; Mukherjee et al., 2002; Riccardi et al., 2007], using both pharmacological challenges as well as functional stimulation tasks [Badgaiyan et al., 2009; Christian et al., 2006; Riccardi et al., 2006a].”
BackgroundMethodInfluentialNagano-Saito, A., Dagher, A., Booij, L., Gravel, P., Welfeld, K., Casey, K. F., Leyton, M., & Benkelfat, C. (2013) · Synapse · doi:10.1002/syn.21700 · Cited by 60
“Based on previous studies (Cropley et al., 2008; Riccardi et al., 2006; Slifstein et al., 2010), and guided by the average [18F]fallypride BPND map obtained from our participants (Fig.”
MethodCentral nervous system effects of haloperidol on THC in healthy male volunteers
Liem-Moolenaar, M., te Beek, E. T., de Kam, M. L., Franson, K. L., Kahn, R. S., Hijman, R., Touw, D., & van Gerven, J. M. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109358200 · Cited by 59
Scott, D. J., Stohler, C. S., Koeppe, R. A., & Zubieta, J. (2007) · Synapse · doi:10.1002/syn.20404 · Cited by 57
“Similar observations were obtained with other DA-releasing agents (e.g., methylphenidate) and with a variety of radiopharmaceuticals targeting DA D2 receptors (Dewey et al., 1991; Endres et al., 1997; Laruelle et al., 1995; Narendran et al., 2004; Riccardi et al., 2006a, 2006b; Volkow et al., 1994).”
ResultOptimized In Vivo Detection of Dopamine Release Using 18F-Fallypride PET
Ceccarini, J., Vrieze, E., Koole, M., Muylle, T., Bormans, G., Claes, S., & Van Laere, K. (2012) · Journal of Nuclear Medicine · doi:10.2967/jnumed.111.099416 · Cited by 57
Blunted Dopamine Transmission in Addiction: Potential Mechanisms and Implications for Behavior
Trifilieff, P., Ducrocq, F., van der Veldt, S., & Martínez, D. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.003 · Cited by 61
Cocaine cue-induced dopamine release in the human prefrontal cortex
Milella, M. S., Fotros, A., Gravel, P., Casey, K. F., Larcher, K., Verhaeghe, J. A. J., Cox, S. M. L., Reader, A. J., Dagher, A., Benkelfat, C., et al. (2016) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.150207 · Cited by 56
Bailer, U. F., Narendran, R., Frankle, W. G., Himes, M. L., Duvvuri, V., Mathis, C. A., & Kaye, W. H. (2012) · International Journal of Eating Disorders · doi:10.1002/eat.20937 · Cited by 55
Riccardi, P., Baldwin, R., Salomon, R. M., Anderson, S., Ansari, M. S., Li, R., Dawant, B. M., Bauernfeind, A. L., Schmidt, D. E., & KESSLER, R. M. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.03.022 · Cited by 60
Self-citationNarendran, R., Jedema, H. P., Lopresti, B. J., Mason, N. S., Gurnsey, K., Ruszkiewicz, J., Chen, C.-M., Deuitch, L., Frankle, W. G., & Bradberry, C. W. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.9 · Cited by 54
A Thalamocorticostriatal Dopamine Network for Psychostimulant-Enhanced Human Cognitive Flexibility
Samanez-Larkin, G. R., Buckholtz, J. W., Cowan, R. L., Woodward, N. D., Li, R., Ansari, M. S., Arrington, C. M., Baldwin, R. M., Smith, C. E., Treadway, M. T., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.10.032 · Cited by 60
“It is this latter property that allows us to measure individual differences in DA responses to d-AMPH in both striatal and extrastriatal regions (25).”
BackgroundSelf-citationImaging Neurotransmitter Release by Drugs of Abuse
Martínez, D., & Narendran, R. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_34 · Cited by 53
“Thus, while dopamine transmission may still be altered by drugs of abuse in the human brain, these alterations may not be measured as robustly with PET.”
In vivo imaging of dopamine receptors in a model of temporal lobe epilepsy
Yakushev, I. Y., Dupont, E., Buchholz, H., Tillmanns, J., Debus, F., Cumming, P. D., Heimann, A., Fellgiebel, A., Luhmann, H. J., Landvogt, C., et al. (2009) · Epilepsia · doi:10.1111/j.1528-1167.2009.02272.x · Cited by 50
“Indeed, [18F]-fallypride binding in vivo is known to be sensitive to endogenous variations of dopamine concentrations in striatal and extrastriatal regions in both humans and animals (Slifstein et al., 2004; Riccardi et al., 2006, 2008).”
BackgroundRominger, A., Wagner, E., Mille, E., Böning, G., Esmaeilzadeh, M., Wängler, B., Gildehaus, F., Nowak, S., Bruche, A., Tatsch, K., et al. (2009) · Synapse · doi:10.1002/syn.20730 · Cited by 50
“In humans, neither amphetamine nor dopamine depletion with AMPT had significant effect on striatal FP binding (Cropley et al., 2008; Riccardi et al., 2006, 2008).”
Eisenstein, S. A., Bischoff, A. N., Gredysa, D. M., Antenor‐Dorsey, J. A. V., Koller, J. M., Al-Lozi, A. M., Pepino, M. Y., Klein, S., Perlmutter, J. S., Moerlein, S. M., et al. (2015) · Scientific Reports · doi:10.1038/srep11283 · Cited by 51
Hsieh, P. C., Yeh, T. L., Lee, I. H., Huang, H. C., Chen, P. S., Yang, Y. K., Chiu, N.-T., Lu, R. B., & Liao, M. (2010) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.090007 · Cited by 51
Riccardi, P., Park, S., Anderson, S., Doop, M. L., Ansari, M. S., Schmidt, D. E., & Baldwin, R. M. (2010) · Synapse · doi:10.1002/syn.20822 · Cited by 51
“We used PET with [18F]fallypride to evaluate whether there are sex differences in d-AMPH-induced DA release (Riccardi et al., 2006b).”
BackgroundMethodInfluentialSelf-citationZald, D. H., Woodward, N. D., Cowan, R. L., Riccardi, P., Ansari, M. S., Baldwin, R. M., Cowan, R. L., Smith, C. E., Hakyemez, H., Li, R., et al. (2010) · NeuroImage · doi:10.1016/j.neuroimage.2010.02.006 · Cited by 49
“The BPND of benzamides such as [18F]fallypride are affected by endogenous DA levels (Riccardi et al. 2005, 2008).”
BackgroundSelf-citationCharacterization of extrastriatal D2 in vivo specific binding of [18F](N‐methyl)benperidol using PET
Eisenstein, S. A., Koller, J. M., Piccirillo, M., Kim, A., Antenor‐Dorsey, J. A. V., Videen, T. O., Snyder, A. Z., Karimi, M., Moerlein, S. M., Black, K. J., et al. (2012) · Synapse · doi:10.1002/syn.21566 · Cited by 44
Laruelle, M. A. (2012) · Neuromethods · doi:10.1007/7657_2012_45 · Cited by 47
Volkow, N. D., Tomasi, D. G., Wang, G., Telang, F., Fowler, J. S., Logan, J., Maynard, L. J., & Wong, C. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.5261-12.2013 · Cited by 45
“A few studies have also reported decreases in BPND in amygdala with [ 11C]raclopride after MP (Volkow et al., 2007b) and with other D2R PET radiotracers after amphetamine administration in humans (Riccardi et al., 2006; Slifstein et al., 2009) and in nonhuman primates (Mukherjee et al., 2005).”
BackgroundBoecker, H., Henriksen, G., Sprenger, T., Miederer, I., Willoch, F., Valet, M., Berthele, A., & Tölle, T. R. (2008) · Methods · doi:10.1016/j.ymeth.2008.07.003 · Cited by 44
Hernaus, D., Collip, D., Lataster, J., Ceccarini, J., Kenis, G., Booij, L., Pruessner, J. C., Laere, K. V., van Winkel, R., van Os, J., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065662 · Cited by 47
“PET measurement of alterations in dopamine concentration in response to a pharmacological manipulation or during a behavioral task can be obtained by calculating the percentage change in dopamine D2/3 receptor BPND (DBPND), measured under dual scanning conditions (control and activation condition) [53,54].”
MethodResultPrasad, K., de Vries, E. F. J., Elsinga, P. H., Dierckx, R., & van Waarde, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041719 · Cited by 44
Automation of the Radiosynthesis of Six Different 18F-labeled radiotracers on the AllinOne
Li, S., Schmitz, A. M. T., Lee, H. S., & Mach, R. H. (2016) · EJNMMI Radiopharmacy and Chemistry · doi:10.1186/s41181-016-0018-0 · Cited by 39
Lee, D. E., Reid, W. C., Ibrahim, W. G., Peterson, K. L., Lentz, M. R., Maric, D., Choyke, P. L., Jagoda, E. M., & Hammoud, D. A. (2014) · Molecular Imaging · doi:10.2310/7290.2014.00031 · Cited by 42
Aalto, S., Hirvonen, J., Kaasinen, V., Hagelberg, N. M., Kajander, J., Någren, K., Seppαlä, T., Rinne, J. O., Scheinin, H., & Hietala, J. A. (2008) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0969-9 · Cited by 38
“Two previous PET studies using [F]fallypride, with no placebo group, have demonstrated significant amphetamine-induced decreases of about 5–12% [30, 31].”
MethodBrain stimulation and functional imaging with fMRI and PET
Ko, J. H., Tang, C. C., & Eidelberg, D. (2013) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53497-2.00008-5 · Cited by 44
18F-Fallypride binding potential in patients with schizophrenia compared to healthy controls
Lehrer, D. S., Christian, B. T., Kirbas, C., Chiang, M., Sidhu, S. S., Short, H., Wang, B., Shi, B., Chu, K.-W., Merrill, B., et al. (2010) · Schizophrenia Research · doi:10.1016/j.schres.2010.03.043 · Cited by 34
“Though striatal 18F-fallypride BPND has values 8–20-fold greater than cortex(Riccardi et al., 2006), the greater volume of individual Brodmann cortical areas or groups of areas (20–300 cm3) than striatal volume (4– 10 cm3) suggests a large and significant role of cortical D2 binding in brain…”
BackgroundThe Sensation Seeking Trait and Substance Use: Research Findings and Clinical Implications
Bardo, M. T., Williams, Y. S., Dwoskin, L. P., Moynahan, S., Perry, I., & Martin, C. A. (2007) · Current Psychiatry Reviews · doi:10.2174/157340007779815682 · Cited by 44
“Using positron emission tomography (PET) [ 18 F]fallypride, a benzamide with high affinity for the dopamine D2/D3 receptor, has been used to visualize and quantify receptor numbers and dopamine release in human striatal and extrastriatal brain regions in response to oral amphetamine [110].”
A perspective on the future role of brain pet imaging in exercise science
Boecker, H., & Drzezga, A. E. (2015) · NeuroImage · doi:10.1016/j.neuroimage.2015.10.021 · Cited by 40
“Finally, both, the opioidergic (DiChiara et al., 1996; Herz, 1996, 1997) anddopaminergic (Fotros et al., 2013; Leyton et al., 2002; Riccardi et al., 2006; Setiawan et al., 2014; Volkow et al., 2003b, 2004) systems are considered as key neurotransmitters for the development and maintenance of…”
Buchsbaum, M. S., Haznedar, M. M., Newmark, R. E., Chu, K.-W., Dusi, N., Entis, J. J., Goldstein, K. E., Goodman, C. R., Gupta, A. K., Hazlett, E. A., et al. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.07.015 · Cited by 34
Counterfactual thinking in moral judgment: an experimental study
Migliore, S., Curcio, G., Mancini, F., & Cappa, S. F. (2014) · Frontiers in Psychology · doi:10.3389/fpsyg.2014.00451 · Cited by 42
Radiopharmaceuticals for positron emission tomography investigations of Alzheimer’s disease
Någren, K., Halldin, C., & Rinne, J. O. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1301-z · Cited by 37
“Recently, a (18)Flabelled tracer for the extra-striatal dopamine D2 receptor, [(18)F]fallypride, has been developed [57, 58].”
Chen, R., Ferris, M. J., & Wang, S. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107583 · Cited by 34
Variability in paralimbic dopamine signaling correlates with subjective responses to d-amphetamine
Smith, C. T., Dang, L. C., Cowan, R. L., KESSLER, R. M., & Zald, D. H. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.05.004 · Cited by 28
“…when interpreting the high incidence of positive and negative % DBPnd in the vmPFC. PET scanning was conducted during a period of relatively stable plasma amphetamine levels starting 3 h after drug administration, similar to previous oral dAMPH protocols with fallypride (Riccardi et al., 2006a).”
BackgroundMethodInfluentialSelf-citationOkita, K., Ghahremani, D. G., Payer, D. E., Robertson, C. L., Mandelkern, M. A., & London, E. D. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv129 · Cited by 29
“Indeed, [18F]fallypride binding in human cortex is responsive to change in intrasynaptic dopamine level induced by administration of amphetamine (Riccardi et al., 2006; Cropley et al., 2008).”
BackgroundNeural and Behavioral Endophenotypes in ADHD
del Campo, N., Müller, U., & Sahakian, B. J. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_200 · Cited by 31
Neuroreceptor Imaging Studies in Schizophrenia
Frankle, G. W. (2007) · Harvard Review of Psychiatry · doi:10.1080/10673220701679812 · Cited by 25
Amphetamine challenge decreases yohimbine binding to α2 adrenoceptors in Landrace pig brain
Landau, A. M., Doudet, D. J., & Jakobsen, S. (2012) · Psychopharmacology · doi:10.1007/s00213-011-2632-6 · Cited by 27
“…2.1 1.5 (29) 2.5 2.2 (13) BASE baseline, AMP amphetamine of extra-striatal amphetamine-induced DA release with high affinity ligands such as FLB457 or fallypride in more DA-sparse regions (cortical, thalamic, and limbic) leads to a similar conclusion (Narendran et al. 2009; Riccardi et al. 2006).”
InfluentialNo evidence for attenuated stress-induced extrastriatal dopamine signaling in psychotic disorder
Hernaus, D., Collip, D., Kasanova, Z., Winz, O., Heinzel, A., van Amelsvoort, T., Shali, S. M., Booij, J., Rong, Y., Piel, M., et al. (2015) · Translational Psychiatry · doi:10.1038/tp.2015.37 · Cited by 23
Eisenstein, S. A., Bogdan, R., Chen, L., Moerlein, S. M., BLACK, K. J., Perlmutter, J. S., Hershey, T. G., & Barch, D. M. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.11.007 · Cited by 25
Selectivity of probes for PET imaging of dopamine D3 receptors
Doot, R. K., Dubroff, J. G., Labban, K. J., & Mach, R. H. (2018) · Neuroscience Letters · doi:10.1016/j.neulet.2018.03.006 · Cited by 25
Noguchi, J., Zhang, M., Yanamoto, K., Nakao, R., & Suzuki, K. (2007) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.09.009 · Cited by 25
Human dopamine receptor D2/D3 availability predicts amygdala reactivity to unpleasant stimuli
Kobiella, A., Vollstädt‐Klein, S., Fauth‐Bühler, M., Graf, C., Buchholz, H., Bernow, N., Yakushev, I. Y., Landvogt, C., Schreckenberger, M., Gründer, G., et al. (2009) · Human Brain Mapping · doi:10.1002/hbm.20900 · Cited by 22
“In support of the first view, displacement PET studies found that [18F]FP was sensitive to endogenous variations of DA concentrations in both striatal and extrastriatal regions in humans [Riccardi et al., 2006, 2008].”
ResultRecent Developments in Molecular Brain Imaging of Neuropsychiatric Disorders
Slifstein, M., & Abi‐Dargham, A. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.002 · Cited by 25
Dunn, J., Clark‐Papasavas, C., Marsden, P. K., Baker, S., Cleij, M. C., Kapur, S., KESSLER, R. M., Howard, R. J., & Reeves, S. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.55 · Cited by 22
Self-citationGerlach, M., Grünblatt, E., & Lange, K. W. (2013) · ADHD Attention Deficit and Hyperactivity Disorders · doi:10.1007/s12402-013-0105-y · Cited by 18
“The ability to increase DA concentrations in the human striatum has also been well established for amphetamine (e.g. Riccardi et al. 2006).”
BackgroundNeurotransmitter Imaging: Basic Concepts and Future Perspectives
Badgaiyan, R. D. (2011) · Current Medical Imaging Formerly Current Medical Imaging Reviews · doi:10.2174/157340511795445720 · Cited by 19
Reproducibility of Post-Amphetamine [11C]FLB 457 Binding to Cortical D2/3 Receptors
Narendran, R., Himes, M. L., & Mason, N. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076905 · Cited by 18
“5 mg kg-1 is consistent with what has been used in previous PET investigations to measured dopamine release in the striatal and extra striatal regions [21-25].”
MethodDunn, J. P., Abumrad, N. N., KESSLER, R. M., Patterson, B. W., Li, R., Marks–Shulman, P. A., & Tamboli, R. A. (2017) · Obesity · doi:10.1002/oby.22023 · Cited by 17
Self-citationSex and the dopaminergic system: Insights from addiction studies
Woodcock, E. A., Zakiniaeiz, Y., Morris, E. D., & Cosgrove, K. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00011-4 · Cited by 15
Arvidsson, E., Viereckel, T., Mikulovic, S., & Wallén‐Mackenzie, Å. (2014) · PLoS ONE · doi:10.1371/journal.pone.0099592 · Cited by 18
van der Laan, L. N., Charbonnier, L., Griffioen-Roose, S., Kroese, F. M., van Rijn, I., & Smeets, P. A. M. (2016) · Biological Psychology · doi:10.1016/j.biopsycho.2016.03.007 · Cited by 14
Antenor‐Dorsey, J. A. V., Markham, J., Moerlein, S. M., Videen, T. O., & Perlmutter, J. S. (2008) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2007.12.004 · Cited by 13
“However, these two ligands, like [11C]raclopride, also are susceptible to displacement by endogenous dopamine [15].”
BackgroundTrifilieff, P., & Martínez, D. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00005-8 · Cited by 15
Amphetamine-induced dopamine release and impulsivity in Parkinson’s disease
Song, A. K., Hay, K. R., Trujillo, P., Aumann, M. A., Stark, A. J., Yan, Y., Kang, H., Donahue, M. J., Zald, D. H., & Claassen, D. O. (2021) · Brain · doi:10.1093/brain/awab487 · Cited by 15
Self-citationTantawy, M. N., Peterson, T. E., Jones, C. K., Johnson, K. A., Rook, J. M., Conn, P. J., Baldwin, R. M., Ansari, M. S., & KESSLER, R. M. (2011) · Synapse · doi:10.1002/syn.20955 · Cited by 12
“Amphetamine causes a drop in the binding of fallypride to D2/3 (Morris and Yoder, 2007; Mukherjee et al., 2005; Narendran et al., 2009; Riccardi et al., 2005; Slifstein et al., 2004).”
BackgroundSelf-citationHow have developments in molecular imaging techniques furthered schizophrenia research?
Thompson, J. L., Urban, N., & Abi‐Dargham, A. (2009) · Imaging in Medicine · doi:10.2217/iim.09.22 · Cited by 9
“DA release: Research has shown that human in vivo binding of both [18F]fallypride and [11C]FLB 457 is vulnerable to acute changes in synaptic DA [98-100].”
BackgroundHuang, W.-S., Chen, G., Tsai, T., Cheng, C.-Y., Shiue, C., Ma, K., & Yeh, S. H. (2019) · EJNMMI Research · doi:10.1186/s13550-019-0557-y · Cited by 13
Radiation dosimetry of N-([11C]methyl)benperidol as determined by whole-body PET imaging of primates
Antenor‐Dorsey, J. A. V., Laforest, R. A., Moerlein, S. M., Videen, T. O., & Perlmutter, J. S. (2007) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-007-0644-6 · Cited by 10
“[ (123)I]Epidepride and [(18)F]fallypride have relatively higher affinity for D2like-specific binding sites than [(11)C]raclopride but remain susceptible to displacement by endogenous dopamine [10].”
BackgroundDarcey, V. L., Guo, J., Chi, M., Chung, S. T., Courville, A. B., Gallagher, I., Herscovitch, P., Howard, R., LaNoire, M., Milley, L., et al. (2025) · Molecular Psychiatry · doi:10.1038/s41380-025-02960-y · Cited by 20
“Despite its high af fi nity for the D2 receptor, [ 18 F]fallypride is somewhat displaceable by manipulations which may increase endogenous dopamine [25, 36, 37].”
Assessment of IP injection of [18F]fallypride for behavioral neuroimaging in rats
Yoder, K. K., Mock, B. H., Zheng, Q., McCarthy, B. P., Riley, A. K., & Hutchins, G. D. (2011) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2010.12.027 · Cited by 9
Hwang, C. J., Choi, D., Jung, Y. Y., Lee, Y.-J., Yun, J. S., Oh, K., Han, S., Oh, S., Park, M. H., & Hong, J. T. (2016) · Hormones and Behavior · doi:10.1016/j.yhbeh.2016.01.011 · Cited by 9
“Studies on human DA release kinetics have shown that women have higher levels of DA release thanmen do (Riccardi et al., 2006).”
BackgroundNarendran, R., Mason, N. S., Himes, M. L., & Frankle, W. G. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.04.001 · Cited by 9
Darcey, V. L., Guo, J., Chi, M., Chung, S. T., Courville, A. B., Gallagher, I., Herscovitch, P., Howard, R., LaNoire, M., Milley, L., et al. (2023) · medRxiv · doi:10.1101/2023.09.27.23296169 · Cited by 9
“Despite its high affinity for the D2 receptor, [18F]fallypride is somewhat displaceable by manipulations which may increase endogenous dopamine (22, 34, 35).”
Background
Metadata
- Authors
- Riccardi, P., Li, R., Ansari, M. S., Zald, D., Park, S., Dawant, B., Anderson, S., Doop, M., Woodward, N., Schoenberg, E., Schmidt, D., Baldwin, R., & Kessler, R.
- Affiliations
- Vanderbilt University (US)
- Corresponding author
- Kessler, Robert
- Venue
- Neuropsychopharmacology
- Published
- 2005-10-19
- Volume
- 31
- Issue
- 5
- Pages
- 1016-1026
- ISSN
- 0893-133X (ISSN-L)
- 1740-634X
- OpenAlex
- W2162421322
- Cited by
- 134
- References
- 104
- Citations by year
- 2025: 3 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 5 · 2019: 2 · 2018: 3 · 2017: 3 · 2016: 12 · 2015: 7 · 2014: 10 · 2013: 12 · 2012: 10
- FWCI
- 2.41
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Neuropsychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (5R01 MH-60898-03, R01MH060898)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Keywords
- d-amphetamine, [18F]fallypride, dopamine D2 receptor, dopamine release, striatum, caudate nucleus, putamen, ventral striatum, substantia nigra, amygdala, temporal cortex, thalamus, sensation seeking, cognition, affect, oral administration
- MeSH terms
- Administration, Oral, Adult, Amphetamine, Amygdala, Basal Ganglia, Benzamides, Binding, Competitive, Brain Mapping, Cognition, Corpus Striatum, Dopamine, Emotions, Exploratory Behavior, Female, Humans, Male, Synaptic Transmission, Pyrrolidines, Radionuclide Imaging, Substantia Nigra, Receptors, Dopamine D2, Dopamine Uptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.